What do you do when you think you were bitten by a tick, but you don’t have the specimen to send in for evaluation? Do you wait for a bulls eye rash? NO! Not all species of Borrelia cause a bulls eye rash. Do you wait to see if you start to feel sick? NO! Not all people feel sick immediately after getting infected. That is why there have been deaths caused by Lyme carditis among people who didn’t even know they had Lyme.
Unfortunately the ELISA antibody test which is the IDSA and CDC’s dictated procedure for someone seeking medical advice or treatment after getting bitten by a tick, is famous for false negatives as it may take up to 3 weeks or more for the body to begin creating antibodies. Unfortunately by then the infection has been drilling into the bodies soft tissue for 3 weeks, and even if a person is treated with antibiotics, a doctor must guess on dosage and duration as thee is no possible way to discern how virulent a new strain may be.
Well, great news came out yesterday (April 21, 2015), that a revolutionary technology has been developed By Ancon Medical, in Minnesota, to determine infection almost instantly.
Quoting the press release:
“Ancon Medical is introducing revolutionary new technology that can make it easier for doctors to diagnose Lyme disease, for which early treatment can usually result in a rapid and complete recovery, according to the Centers for Disease Control.
“Ancon Medical’s Nanoparticle Biomarker Tagging (NBT) device can screen for a wide range of diseases by testing an individual’s exhaled breath for biomarkers, which act as a chemical fingerprint for the presence of disease.”
“If Lyme disease is discovered early, and treated early, a patient can make a full recovery. But if treatment isn’t delivered until later, then a patient can suffer chronic symptoms from the disease,” said Wesley Baker, Ancon Medical Chief Executive Officer. “Ancon Medical’s NBT technology has the promise to give doctors early screening capabilities for Lyme disease, allowing for quicker treatment and better results for people infected with the disease.”
To become an effective screening device for Lyme disease, more research and funding will be needed to discover the chemical biomarker for Lyme disease. Furthermore, more research into the Lyme disease biomarker could expand the value of NBT technology to the veterinary field, as the disease has been diagnosed in dogs, cats, horses, goats, sheep and cattle.
“By applying our revolutionary new NBT technology to veterinary medicine, Ancon Medical can make it easier for vets, farmers and agricultural professionals to detect Lyme disease in their animals and better manage their livestock,” Baker said.
Ancon Medical, and its associated company Ancon Research Ltd., has patents on NBT technology in both the U.S. and U.K. Ancon Medical is a member of LifeScience Alley, a biomedical trade association based in Minnesota.
This is a step in the right direction. Many medical scientists agree that the antibody tests that have been used for the last 3 decades are ineffective for such a complex infection and by screening the infection when the bacteria is vulnerable in the blood stream is the easiest time to eradicate it completely. Unfortunately it (Borrelia) can invade the central nervous system in a matter of minutes.